Treatment of 8 hypertensive elderly subjects with atenolol or with labetalol did not affect exercise performance, except after the development of circulatory congestion in 1 patient. Treatment with beta blockers did not alter the response to an exercise training programme in 15 elderly patients with ischaemic heart disease, as compared with 11 patients without such treatment.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/eurheartj/5.suppl_e.117 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Modified Delphi expert elicitation of the clinical and economic burden of obstructive hypertrophic cardiomyopathy in England and Northern Ireland.
BMJ Open
December 2024
Institute for Cardio-Metabolic Medicine, University Hospital Coventry & Warwickshire NHS Trust, University of Warwick Medical School and Coventry University, Coventry, UK
Objective: To estimate the resource use of patients with obstructive hypertrophic cardiomyopathy (HCM), stratified by New York Heart Association (NYHA) class, in the English and Northern Irish healthcare systems via expert elicitation.
Design: Modified Delphi framework methodology.
Setting: UK HCM secondary care centres (n=24).
Beta-Blockers and Cutaneous Melanoma Outcomes: A Systematic Review and Random-Effects Meta-Analysis.
Pigment Cell Melanoma Res
January 2025
Dermatology Research Centre, Frazer Institute, The University of Queensland, Brisbane, Australia.
Beta-blockers have generated an exciting discourse for their potential as a cheap, safe, and effective adjunctive therapy for cutaneous melanoma patients, but the field remains murky. This systematic review investigates the association between beta-blocker use and survival outcomes in cutaneous melanoma patients. We reviewed 12 studies with 21,582 patients in a network meta-analysis and found a benefit between beta-blocker use and disease-free survival but no other significant association for melanoma-specific or overall survival.
View Article and Find Full Text PDFIn Light of the LANDI-SEP Trial: New Evidence or Double Jeopardy?
Indian J Crit Care Med
January 2025
Department of Critical Care Medicine, Ruby Hall Hospital, Pune, Maharashtra, India.
Datta PK, Sathe P, Bhattacharjee A, Kundu R. In Light of the LANDI-SEP Trial: New Evidence or Double Jeopardy? Indian J Crit Care Med 2025;29(1):84-85.
View Article and Find Full Text PDFFactors Associated With the Recovery of Left Ventricular Ejection Fraction in Patients With Anthracycline-Induced Left Ventricular Dysfunction.
J Cardiovasc Pharmacol Ther
January 2025
Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, MI, USA.
Background: Neurohormonal blocking drugs, like beta-blockers, angiotensin-converting enzyme inhibitors (ACEIs), and angiotensin receptor blockers (ARBs), are recommended for treating anthracycline-induced left ventricular dysfunction (AILVD). However, there is limited evidence supporting their benefit. Therefore, this study evaluated associations of neurohormonal blockers and other clinical factors with recovery of left ventricular ejection fraction (LVEF) in patients with AILVD.
View Article and Find Full Text PDFThe latest in clinical trial results of 5-alpha reductase inhibitors in combination regimens for benign prostatic hyperplasia.
Expert Opin Pharmacother
January 2025
Department of Urology, Sismanoglio General Hospital, National and Kapodistrian University of Athens, Greece.
Introduction: BPH/male LUTS is a prevalent condition in the aging male population with multifactorial pathophysiology. Pharmacotherapy remains the cornerstone of treatment in patients who fail conservative treatment. 5-alpha-reductase inhibitors (5-ARIs) is the only class of medication shown to reduce the risk of acute retention and BPH-related surgery and thus, are commonly used along with other 'short acting' medications in combination treatments.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!